Intervention not reported
BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).
1 finding from 1 review
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · CVD (ASCVD, HF, or both)
DPP4i showed no clear difference in cardiovascular mortality compared with placebo (high certainty).
1 finding from 1 review
Cardiovascular mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower cardiovascular mortality compared with placebo (high certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in myocardial infarction (fatal or non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower stroke (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in hospitalisation for HF compared with placebo (high certainty).
1 finding from 1 review